Delfi enrolls first participants in liquid biopsy lung cancer trial

2019 09 09 20 46 2283 Lung Cancer 400

Delfi Diagnostics has enrolled the first participants in a trial to evaluate a liquid biopsy test for early lung cancer detection in people who are receiving CT lung cancer screening.

The CASCADE-LUNG study is expected to enroll 15,000 patients and aims to clinically validate Delfi's test, which detects a blood-based signal of undiagnosed lung cancer. It is a prospective, multicenter trial that will enroll participants at the time of their low-dose computed tomography (LDCT) lung cancer scans.

This trial will complement another study that was launched in 2021 and designed to develop and validate Delfi's machine-learning based cancer detection test.

Page 1 of 7
Next Page